SITE011-0316

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE011 (ITA) · Dr. Jansen
consented 2023-03-13

AEs

Serious

Dropout signal

–

Adverse events

severe serious assessed

Grade 4 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-04-07 (study day 15); relationship: not assessed; serious criteria: life-threatening

moderate assessed

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-05-06 (study day 44); relationship: not assessed

mild assessed

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-06-09 (study day 78); relationship: not assessed

severe assessed

Grade 3 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-06-18 (study day 87); relationship: not assessed

mild assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-06-28 (study day 97); relationship: not assessed

Data queries

No data queries.